Skip to main content

Roche banks on new drug data to defend cancer business

Swiss drugmaker Roche hopes data published this week will show it has a viable follow-on product to help fend off cheaper competition for its best-selling cancer drug, which loses patent protection in Europe later this year.

 

Roche is set to present full results early on Thursday of a late-stage study for its GA101 drug in chronic lymphocytic leukaemia (CLL), ahead of the American Society of Clinical Oncology annual meeting in Chicago from May 31 to June 4.

Niko Andre, Roche's head of medical affairs for oncology, said the data would make clear GA101's true potential as a new treatment option in CLL. "The data will speak for themselves," he said.

Roche is the world's largest maker of cancer drugs and GA101 is a key test of its ability to defend its business against cheaper copies, known as "biosimilars" because they are not identical matches of branded medicines.

GA101 is a follow-on to Roche's top-seller MabThera, also known as Rituxan. The treatment for blood cancer and rheumatoid arthritis had sales of $7 billion in 2012, but goes off patent in Europe at the end of this year.

The new drug typifies Roche's strategy of protecting its existing sales once top sellers lose exclusivity by developing better versions of its original medicines.

Roche has already made a running start in protecting its breast cancer drug Herceptin - off patent next year - by winning approval for two new drugs against the disease, Perjeta and Kadcyla.

Although the GA101 data are just for CLL, which is a smaller treatment area than non-Hodgkin's Lymphoma (NHL) and accounts for roughly 15 to 20 percent of Rituxan sales, analyst Fabian Wenner at brokerage Kepler Chevreux thinks the data will provide a good indication of its potential efficacy in NHL.

"NHL will be the real acid test. But the full data (in CLL) are the first kind of validation and that's important," Wenner said. "Headline data have shown a stronger efficacy and a longer endurance in the body, which bodes well for NHL."

Analysts and investors are also keen to see head-to-head data comparing GA101 with Rituxan, which will be presented at the American Society of Hematology meeting in December.

Roche said in January an analysis after the first stage of the comparative trial showed there is a possibility that GA101 will be better than Rituxan.

"The market was once worried about biosimilars eroding two of Roche's largest products from 2014 onwards," Deutsche bank analysts wrote in a note.

"Although Roche cannot fully protect them, Perjeta and Kadcyla in breast cancer and now GA101 give confidence of a continued profit stream in both a branded and biosimilar environment."

Popular posts from this blog

Study Abroad USA, College of Charleston, Popular Courses, Alumni

Thinking for Study Abroad USA. School of Charleston, the wonderful grounds is situated in the actual middle of a verifiable city - Charleston. Get snatched up by the wonderful and customary engineering, beautiful pathways, or look at the advanced steel and glass building which houses the School of Business. The grounds additionally gives students simple admittance to a few major tech organizations like Amazon's CreateSpace, Google, TwitPic, and so on. The school offers students nearby as well as off-grounds convenience going from completely outfitted home lobbies to memorable homes. It is prepared to offer different types of assistance and facilities like clubs, associations, sporting exercises, support administrations, etc. To put it plainly, the school grounds is rising with energy and there will never be a dull second for students at the College of Charleston. Concentrate on Abroad USA is improving and remunerating for your future. The energetic grounds likewise houses various

Best MBA Online Colleges in the USA

“Opportunities never open, instead we create them for us”. Beginning with this amazing saying, let’s unbox today’s knowledge. Love Business and marketing? Want to make a high-paid career in business administration? Well, if yes, then mate, we have got you something amazing to do!   We all imagine an effortless future with a cozy house and a laptop. Well, well! You can make this happen. Today, with this guide, we will be exploring some of the top-notch online MBA universities and institutes in the USA. Let’s get started! Why learn Online MBA from the USA? Access to More Options This online era has given a second chance to children who want to reflect on their careers while managing their hectic schedules. In this, the internet has played a very crucial in rejuvenating schools, institutes, and colleges to give the best education to students across the globe. Graduating with Less Debt Regular classes from high reputed institutes often charge heavy tuition fees. However onl

Sickening moment maskless 'Karen' COUGHS in the face of grocery store customer, then claims she doesn't have to wear a mask because she 'isn't sick'

A woman was captured on camera following a customer through a supermarket as she coughs on her after claiming she does not need a mask because she is not sick.  Video of the incident, which has garnered hundreds of thousands of views on Twitter alone, allegedly took place in a Su per Saver in Lincoln, Nebraska according to Twitter user @davenewworld_2. In it, an unidentified woman was captured dramatically coughing as she smiles saying 'Excuse me! I'm coming through' in the direction of the customer recording her. Scroll down for video An unidentified woman was captured dramatically coughing as she smiles saying 'Excuse me! I'm coming through' in the direction of a woman recording her A woman was captured on camera following a customer as she coughs on her in a supermarket without a mask on claiming she does not need one because she is not sick @chaiteabugz #karen #covid #karens #karensgonewild #karensalert #masks we were just wearing a mask at the store. ¿ o